10x Genomics Announces Collaboration with Berry Genomics to Develop Next Generation Noninvasive Prenatal Testing (NIPT)

–Collaboration will be a new service offering for Berry Genomics and entry point for 10x Genomics into the NIPT Market in China– PLEASANTON, CA. and BEIJING, CHINA —January 8, 2018—10x Genomics, Inc., a company focused on accelerating genomic discovery, and Berry Genomics Co. Ltd (SZSE:000710), a company devoted to developing and offering genomic solutions for... Read more

GE, Roche Enter Partnership to Develop Integrated Digital Diagnostics Platform to Improve Oncology and Critical Care Treatment

Chicago, USA Jan 8, 2018 – GE Healthcare has entered into a strategic, long-term partnership with Roche (SIX: RO, ROG; OTCQX: RHHBY) to jointly develop and co-market digital clinical decision support solutions. The partnership will initially focus on products that accelerate and improve individualized treatment options for cancer and critical care patients. The two companies... Read more

Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment

Basel, 08 January 2018 Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment Companies aim to develop jointly-branded clinical decision support software for faster, more accurate, more confident decision-making, enabling earlier diagnosis and individualised treatment Partnership will apply advanced analytics to in-vivo data from GE’s medical... Read more

Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment

Basel, 08 January 2018 Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment Companies aim to develop jointly-branded clinical decision support software for faster, more accurate, more confident decision-making, enabling earlier diagnosis and individualised treatment Partnership will apply advanced analytics to in-vivo data from GE’s medical... Read more

Illumina and KingMed Diagnostics Partner to Develop Next-Generation Sequencing Technology for Chinese FDA Approval

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) and KingMed Diagnostics (SSE: 603882.SS) today announced an agreement to jointly develop novel oncology and hereditary disease testing applications utilizing Illumina’s next-generation sequencing (NGS) technology. The collaboration is a significant step toward China Food and Drug Administration (CFDA) review and approval, and serves as a starting point to deliver... Read more

BIO-TECHNE ACQUIRES ATLANTA BIOLOGICALS INC.

MINNEAPOLIS, Jan. 2, 2018 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) announced today that it has acquired all of the stock of Atlanta Biologicals, Inc. and its affiliated company, Scientific Ventures, Inc.. The transaction is financed through available cash on hand. Charles R. Kummeth, President and Chief Executive Officer of Bio-Techne, commented, “Atlanta Biologicals is a great... Read more

Thermo Fisher Scientific Completes Acquisition of Phenom-World

WALTHAM, Mass., Dec. 29, 2017 /PRNewswire/ — Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has completed the acquisition of Phenom-World, a leader in desktop scanning electron microscopy (SEM) solutions. Thermo Fisher will integrate the business into Thermo Fisher’s Analytical Instruments segment. Terms of the transaction were not disclosed. Based in... Read more

BD Completes Bard Acquisition, Creating New Global Health Care Leader

FRANKLIN LAKES, N.J., Dec. 29, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of C. R. Bard, Inc. (NYSE: BCR), creating a new health care industry leader with approximately $16 billion in annualized revenue. The combined company is uniquely positioned to... Read more

BD Announces Expiration and Final Results of Exchange Offers and Consent Solicitations for C. R. Bard, Inc. Notes

FRANKLIN LAKES, N.J., Dec. 29, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX) announced today the expiration and final results of its previously announced offers to exchange (the “Exchange Offers”) any and all outstanding 4.400% Notes due 2021, 3.000% Notes due 2026 and 6.700% Notes due 2026 (collectively, the “Bard Notes”) issued by C.... Read more

BD Announces Extension of Exchange Offers and Consent Solicitations for C. R. Bard, Inc. Notes

FRANKLIN LAKES, N.J., Dec. 28, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that, in connection with its previously announced offers to exchange (the “Exchange Offers”) any and all outstanding 4.400% Notes due 2021, 3.000% Notes due 2026 and 6.700% Notes due 2026 (collectively, the “Bard Notes”) issued by C. R. Bard, Inc. (“Bard”) for new... Read more